CryoPort Inc (OTCMKTS:CYRX)‘s stock had its “outperform” rating restated by stock analysts at Cowen and Company in a report released on Friday. They presently have a $5.50 price objective on the consumer goods maker’s stock. Cowen and Company’s price target would suggest a potential upside of 17.52% from the stock’s current price.

CYRX has been the topic of several other research reports. Needham & Company LLC raised their target price on CryoPort from $3.50 to $4.50 and gave the company a “buy” rating in a research report on Thursday, June 1st. ValuEngine upgraded CryoPort from a “sell” rating to a “hold” rating and set a $122.00 target price on the stock in a research report on Friday, May 12th.

CryoPort (CYRX) opened at 4.68 on Friday. CryoPort has a 12-month low of $1.50 and a 12-month high of $4.75. The stock’s market capitalization is $112.20 million. The company has a 50-day moving average price of $3.35 and a 200-day moving average price of $3.12.

WARNING: “CryoPort Inc (CYRX) Rating Reiterated by Cowen and Company” was originally posted by American Banking News and is owned by of American Banking News. If you are viewing this article on another domain, it was illegally stolen and republished in violation of international copyright & trademark legislation. The original version of this article can be accessed at https://www.americanbankingnews.com/2017/06/17/cryoport-inc-cyrx-rating-reiterated-by-cowen-and-company.html.

About CryoPort

Cryoport, Inc (Cryoport) is a provider of cryogenic logistics solutions to the life sciences industry through its purpose-built packaging, information technology and specialized cold chain logistics expertise. The Company provides logistics solutions for biologic materials, such as immunotherapies, stem cells, chimeric antigen receptors (CAR)-T cells, and reproductive cells for clients.

Receive News & Ratings for CryoPort Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CryoPort Inc and related companies with MarketBeat.com's FREE daily email newsletter.